Sunitinib-platinum(IV) prodrug-1 Preis auf Anfrage
Artikelnummer:
TGM-T214353
Hersteller Artikelnummer:
T214353
Alternativnummer:
TGM-T214353-10MG,TGM-T214353-50MG
Hersteller:
TargetMol
Kategorie:
Biochemikalien
Sunitinib-platinum(IV) prodrug-1 (Complex A) is a Cisplatin-based Pt(IV) prodrug designed to be reduced to active Pt(II) in intracellular reductive conditions, while concurrently releasing a sunitinib derivative with tyrosine kinase inhibitor (TKI) activity. This compound exhibits remarkable cytotoxicity against renal cell carcinoma (RCC), inducing DNA crosslinking and apoptosis. It inhibits VEGFR/PDGFR signaling pathways, thereby suppressing tumor growth and angiogenesis, and can be used for studying RCC.
